53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
At CHEST 2025, held in Chicago, Illinois, Laurie Slovarp, PhD, CCC-SLP, professor at the University of Montana and certified speech pathologist, presented a poster on the development of a digital therapeutic designed to improve access to behavioral cough suppression therapy for patients with refractory chronic cough.
A large-scale trial examining the effect of azithromycin on the relationship between oesophageal function and cough as evaluated by Hyfe's cough monitoring technology in respiratory disease is feasible and acceptable to patients.
This study used Hyfe's wearable cough monitor during a 7-day run in, 28-day treatment, and 14-day follow-up period in patients with chronic bronchitis.
Periods of intense coughing (termed bouts, epochs or bursts) are particularly problematic for some coughers and may not be reflected by simply counting the number of coughs per day. This study explored how varying the definition of bouts yield different impressions of cough severity.
Risk scores are used throughout medical care to guide treatments, allocate resources, and control outbreaksof disease. Though valuable, most risk scores are limited by their basis in aging datasets and their use withpatients in single, time-constrained consultations. Mobile health could collect longitudinal or even continuousdata on patient health. Automated, dynamic, and real-time risk profiles could trigger earlier interventions, improveclinical outcomes, guide resource distribution, and preempt outbreaks.
Dynamic risk profiles hold enormouspotential for global health, and smartphones are now uniquely equipped and positioned to unlock that potential.We identify cough, an information-rich and readily monitored syndrome, as the symptom that will pioneer ’smartrisk profiling’ systems, prove their value in alleviating the global burden of respiratory disease, and usher in anew era of proactive mobile health.
